Lazertinib was approved for the first time for the treatment of EGFR T790M mutation‐positive patients with locally advanced or metastatic NSCLC who had previously received EGFR‐TKI therapy.146. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.